Can-Fite BioPharma Ltd. CANF
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -59.50%
- 1 year
- -81.16%
- Open
- 1.68
- Prev close
- 1.66
- Mkt cap
- 4.91M
- Vol
- 22.44K
- Avg vol
- 376.27K
- EPS
- -13.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.60
- High
- 1.70
- Forward P/E
- -2.00
- Beta
- 0.57
- Short ratio
- 1.96
- Inst. own
- 8.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.08
- 200-d avg
- 2.37
- 1y target
- 14.00
News
-
6 days ago benzinga.com
Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months…
6 days ago globenewswire.com
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39…
1 month ago globenewswire.com
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel,…
-
1 month ago benzinga.com
Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of…
1 month ago globenewswire.com
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
2 months ago benzinga.com
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
2 months ago benzinga.com
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
-
2 months ago benzinga.com
Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological…
2 months ago globenewswire.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
-
2 months ago benzinga.com
Can-Fite Says Blinded Overall Survival Observed Across Entire Patient Population In Ongoing Pivotal Phase III Study Of Namodenoson In Advanced HCC Appears Longer Than Originally Anticipated Based On Assumptions Underlying Study Design
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases,…
2 months ago globenewswire.com
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
-
2 months ago benzinga.com
Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.…
2 months ago globenewswire.com
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE…
2 months ago globenewswire.com
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) --…
-
3 months ago benzinga.com
Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive resultsRamat Gan, Israel, Aug. 03, 2026 (GLOBE…
3 months ago globenewswire.com
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE…
-
3 months ago benzinga.com
Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases,…
3 months ago globenewswire.com
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
3 months ago globenewswire.com
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small…
-
3 months ago benzinga.com
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis
Interim analysis to be conducted under an FDA- and EMA-agreed protocolRamat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage…
3 months ago globenewswire.com
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a…
4 months ago benzinga.com
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ:RGC) stock moved…
4 months ago benzinga.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, with updated follow-up data…
4 months ago benzinga.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.
4 months ago globenewswire.com
Wall Street is Watching These Biotechs
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International…
-
4 months ago benzinga.com
Market-Moving News for July 1st
NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom Energy shares are trading higher after the company announced it expanded its AI infrastructure…
4 months ago globenewswire.com
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
4 months ago benzinga.com
Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case
Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic disease opportunity.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-market session. The company's market cap stands at $33.0 million. INVO Fertility (NASDAQ:IVF) shares…
-
4 months ago benzinga.com
Market-Moving News for June 26th
ON: -14% | ON stock has given up its prior gain. ON Semiconductor shares were trading higher after the company announced it will acquire Synaptics. IVF: 84% | INVO Fertility Acquires HRCFG For…
-
4 months ago benzinga.com
Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseasesRamat Gan, Israel, June…
4 months ago globenewswire.com
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June…
-
4 months ago benzinga.com
Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article Showing Broad Therapeutic Potential Of Lead Drug Candidates, Piclidenoson And Namodenoson, Across Multiple Major Diseases
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced…
4 months ago globenewswire.com
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that…
4 months ago globenewswire.com
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)…
-
5 months ago benzinga.com
Can-Fite Highlights Pancreatic Cancer Drug Progress
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory…
5 months ago globenewswire.com
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism
Growing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 months ago benzinga.com
Nasdaq Surges Over 1%; ISM Services PMI Tops Views
U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.
8 months ago benzinga.com
Dow Surges 100 Points; Abercrombie & Fitch Shares Fall After Q4 Results
US stocks rise, with Dow up 0.25% and NASDAQ up 0.69%. Consumer discretionary shares increase by 1.1%, while energy stocks dip by 0.6%.
-
8 months ago benzinga.com
Market-Moving News for March 4th
MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences. CANF: 54% | Can-Fite